Insulin Glargine U-300 Max Injection, Solution
Product Images NDC 0955-2900

Product Visual Gallery

This gallery contains 51 technical images submitted to the FDA as part of the official labeling for Insulin Glargine U-300 Max (NDC 0955-2900). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Insulin Glargine 01)

A line graph depicting glucose infusion rate (GIR) in mg/kg*min versus time after subcutaneous injection in hours. The graph shows the GIR profile following treatment with insulin glargine at a dose of 0.4 units/kg, illustrating changes over a 36-hour period.*

FDA Label Image

Image (Insulin Glargine 02)

An anatomical illustration highlighting recommended subcutaneous injection sites for insulin administration. The diagram marks the upper arms, stomach, and thighs in green on a human figure as preferred injection areas.*

FDA Label Image

Image (Insulin Glargine 03)

An illustration showing a detailed diagram of an insulin injection pen labeled Insulin glargine U-300 Max SoloStar with components identified, including pen cap, cartridge holder, rubber seal, insulin scale, plunger, insulin name label, dose window, dose pointer, dose selector, injection button, and a note indicating the plunger becomes visible only after several doses are injected.*

FDA Label Image

Image (Insulin Glargine 04)

The image shows a label on an Insulin glargine U-300 SoloStar injection pen. It indicates the product name Insulin glargine U-300, with a strength of 300 units/mL (U-300). The label also notes it is for single-patient use only. The pen is white with a dosage dial visible on one end.*

FDA Label Image

Image (Insulin Glargine 05)

Insulin glargine U-300 injection solution pen showing a white label with a QR code and printed lot number and expiration date. The pen is white with a green end cap. Manufacturer is Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Insulin Glargine 06)

An instructional diagram showing a person holding an Insulin glargine U-300 injection pen. The left side depicts the pen with dosage markings, and the right side shows the pen cap being pushed off horizontally, indicated by a rightward-pointing arrow.*

FDA Label Image

Image (Insulin Glargine 07)

Label panel of Insulin glargine U-300 injection, solution showing a strength of 300 units per mL. The label includes instructions for subcutaneous use and a white blank space intended for additional information or labeling. The product is labeled by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Insulin Glargine 08)

An instructional illustration showing a person holding an insulin injection pen or cartridge, using a piece of paper or cloth to clean or prepare it before use. The image depicts hand placement and preparation technique for subcutaneous injection of insulin glargine U-300 solution.*

FDA Label Image

Image (Insulin Glargine 09)

An instructional illustration showing two hands opening or removing the cap from a small vial or container, likely demonstrating preparation steps for an injection.*

FDA Label Image

Image (Insulin Glargine 10)

An instructional illustration showing how to remove the cap from an Insulin glargine U-300 injection pen. Two hands hold the pen while twisting and pulling the cap off, indicated by blue arrows, with a red circle and slash highlighting an incorrect method of removing the cap by pulling it straight off without twisting.*

FDA Label Image

Image (Insulin Glargine 11)

An instructional illustration showing the insulin glargine U-300 injection pen with a focus on priming the pen. The user’s hand is depicted pressing the pen against a surface while removing the cap from the pen needle, typically part of preparation steps before subcutaneous injection.*

FDA Label Image

Image (Insulin Glargine 12)

An instructional illustration depicting a hand removing a cap from an insulin pen and showing the pen positioned above an open container, likely demonstrating the preparation or disposal process for insulin glargine U-300 injection solution, subcutaneous use.*

FDA Label Image

Image (Insulin Glargine 13)

An instructional illustration showing how to set the dose on an Insulin glargine U-300 SoloStar pen injector. The image depicts hands turning the dosage selector dial with a close-up of the dial indicating dose increments around the numbers 2 and 4.*

FDA Label Image

Image (Insulin Glargine 14)

An instructional illustration showing hands holding an insulin pen injecting solution. A close-up circle emphasizes the needle tip dispensing a spray of liquid, indicating the injection process for the insulin glargine U-300 solution for subcutaneous use.*

FDA Label Image

Image (Insulin Glargine 15)

Insulin glargine U-300 injection in a SoloStar prefilled pen device. The image shows the pen with a visible 300 units/mL strength marking on the dose window, a green dosage scale, and a white dose selector dial. The label indicates this injection is for subcutaneous use, labeled by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Insulin Glargine 16)

Instructional illustration showing how to cap or uncap an Insulin glargine U-300 SoloStar prefilled pen injector. The pen is held horizontally with one hand, and the other hand is shown turning the green cap with an upward arrow indicating the direction of movement.*

FDA Label Image

Image (Insulin Glargine 17)

Close-up image of a dosage selector dial on an insulin injection device showing dose increments, marked with numbers 28, 30, and 32, used for precise dose adjustment.*

FDA Label Image

Image (Insulin Glargine 18)

An illustration showing a close-up detail of an insulin pen dose selector, highlighting the numbers 28 and 30 on a numbered dial. This image likely relates to dose setting for insulin administration.*

FDA Label Image

Image (Insulin Glargine 19)

An instructional illustration showing a hand holding an insulin glargine U-300 injection pen. The image demonstrates how to use the pen, with an arrow pointing left, indicating the direction for removing the needle cap or preparing the device for injection.*

FDA Label Image

Image (Insulin Glargine 20)

An instructional diagram showing the correct method to unlock the dose knob on an insulin pen. It illustrates holding the pen and turning the dose knob to the correct alignment marked within a blue circle, with a red circle showing an incorrect knob position to avoid.*

FDA Label Image

Image (Insulin Glargine 21)

An instructional diagram demonstrating the proper use of an insulin glargine U-300 injection pen. The image shows a hand holding the injection pen subcutaneously, with zoomed-in views highlighting the injection technique, including pressing the pen and holding it for 5 seconds to ensure proper delivery of the dose.*

FDA Label Image

Image (Insulin Glargine 22)

An instructional illustration showing how to attach a needle to a prefilled insulin syringe pen. The syringe displays a dose scale marked with units, and arrows indicate the direction to connect the needle to the pen. The pen label partially shows "Insulin glargine U-300."*

FDA Label Image

Image (Insulin Glargine 23)

Illustration showing hands manipulating an insulin glargine U-300 injection pen. The cap is being twisted or removed from the pen prior to injection, with arrows indicating the direction of rotation and pressure applied on the pen cap.*

FDA Label Image

Image (Insulin Glargine 24)

An instructional illustration showing a hand removing the cap from a vial and another hand holding a small adapter piece above the vial opening, indicating a step in the preparation or use of an injectable medication.*

FDA Label Image

Image (Insulin Glargine 25)

An instructional diagram showing hands removing the cap from an Insulin glargine U-300 injection pen. A blue arrow indicates the direction to pull the pen cap off before use, illustrating part of the preparation process for subcutaneous injection.*

FDA Label Image

Image (Insulin Glargine 26)

An anatomical illustration showing recommended injection sites for subcutaneous use of insulin glargine. Highlighted areas in green include the upper arms, stomach, and thighs on a human figure.*

FDA Label Image

Image (Insulin Glargine 27)

An instructional illustration of the Insulin glargine U-300 injection pen. Labeled parts include pen cap, cartridge holder, rubber seal, insulin scale, plunger (visible after several doses), insulin name label with strength and dosage info, dose window, dose pointer, dose selector, and injection button. It shows assembly and dose-setting components of the pen.*

FDA Label Image

Image (Insulin Glargine 28)

Insulin glargine U-300 Max SoloStar injection pen label showing a subcutaneous solution with a strength of 300 units/mL (U-300). The label includes dosing instructions indicating it adjusts by 2 units and specifies it is for single patient use only. The product is by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Insulin Glargine 29)

Image of a Sanofi-Aventis U.S. LLC Insulin glargine U-300 injection pen with a visible lot number and expiration date. The pen is a beige-colored subcutaneous injection device for insulin glargine 300 [iU]/mL solution.*

FDA Label Image

Image (Insulin Glargine 30)

An instructional illustration showing the assembly of an insulin glargine U-300 pen injection device. The image depicts a hand holding the insulin cartridge and aligning it with the pen injector, indicated by a blue arrow pointing toward the pen assembly.*

FDA Label Image

Image (Insulin Glargine 31)

Insulin glargine U-300 300 units/mL injection solution pen for subcutaneous use by Sanofi-Aventis U.S. LLC. The image shows a close-up of the insulin pen with a visible dosage window and partial label indicating dosage strength and basic usage instructions. The pen is designed for precise dosing with a visible dial and threaded end for needle attachment.*

FDA Label Image

Image (Insulin Glargine 32)

An instructional illustration showing hands removing a protective cap from the tip of an insulin injection pen, indicating preparation for subcutaneous injection use.*

FDA Label Image

Image (Insulin Glargine 33)

Illustration showing two hands preparing a vial by removing a flip-off cap, commonly used for injections like insulin glargine U-300 subcutaneous solution. The image demonstrates safe vial preparation prior to use.*

FDA Label Image

Image (Insulin Glargine 34)

An instructional illustration showing hands preparing an Insulin glargine U-300 injection solution pen. The image depicts removing the cap by pulling it outward and unscrewing the needle cover by twisting in a counterclockwise direction, with directional arrows indicating the steps for safe handling before subcutaneous injection.*

FDA Label Image

Image (Insulin Glargine 35)

An instructional illustration showing a hand holding a vial of Insulin glargine U-300 injection solution and another hand removing the protective cap from the vial, demonstrating preparation steps for subcutaneous use.*

FDA Label Image

Image (Insulin Glargine 36)

An instructional illustration showing a hand removing a cap from a small needle while another hand holds an insulin pen injector above an open vial. The diagram suggests preparation steps for subcutaneous injection of insulin glargine U-300 solution.*

FDA Label Image

Image (Insulin Glargine 37)

An instructional illustration showing a person adjusting the dose on an Insulin glargine U-300 injection pen. The dial on the pen is being turned to select 4 units, highlighted in a circular close-up. The pen is labeled with the product name and strength, 300 units per mL.*

FDA Label Image

Image (Insulin Glargine 38)

An instructional illustration showing the proper technique for priming or expelling air from an insulin syringe or pen. It depicts hands holding the injection device with fluid being ejected from the needle tip, indicated by an arrow and a magnified inset of fluid spray.*

FDA Label Image

Image (Insulin Glargine 39)

Insulin glargine U-300 Max SoloStar injection pen showing 300 units/mL strength. The label displays dosage marks, the product name with nonproprietary insulin glargine, and a dosage adjustment indication in blue. The pen is designed for subcutaneous injection and labeled by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Insulin Glargine 40)

An instructional illustration showing how to adjust the dose on an Insulin glargine U-300 Max SoloStar injection pen by turning the dose selector dial clockwise as indicated by a blue arrow. The pen displays the strength 300 [iU]/mL and includes dose adjustment markings.*

FDA Label Image

Image (Insulin Glargine 41)

An illustration showing a dial window with numerical increments, likely representing dose units for an insulin injection pen. The visible numbers are 56, 60, and 64, indicating adjustable dosing increments for insulin glargine U-300 injection.*

FDA Label Image

Image (Insulin Glargine 42)

An illustration showing a close-up of the dose selector window on an insulin pen, displaying a dose range from 56 to 60 units. The dial is beige with black numbers and a white background, used for adjusting the insulin glargine U-300 injection dose.*

FDA Label Image

Image (Insulin Glargine 43)

An instructional illustration showing a hand holding an insulin pen for subcutaneous injection. The pen is positioned against the skin with a needle inserted. A blue arrow indicates pulling the pen outward to remove it after injection.*

FDA Label Image

Image (Insulin Glargine 44)

An instructional illustration showing how to correctly turn the dose selector on an insulin glargine U-300 injection pen. The hand grips the pen with the thumb on the green dose selector dial, turning it counterclockwise to select the dose. A close-up view highlights the correct rotation direction with a blue arrow and the numbers 16, 20, and 24 visible on the dial. A red circle with a slash indicates that pressing or pushing down on the dial is incorrect.*

FDA Label Image

Image (Insulin Glargine 45)

An instructional illustration showing the administration of Insulin glargine U-300 injection solution subcutaneously. The image includes a close-up of a hand pressing the injector pen, a dial set to zero, and a clock icon indicating to hold for 5 seconds after injection.*

FDA Label Image

Image (Insulin Glargine 46)

An instructional illustration showing a hand turning the cap of an Insulin glargine U-300 injection pen. The visible part of the syringe barrel is marked with unit calibration numbers up to 900, indicating dose measurement. The diagram includes a blue arrow indicating the direction to turn the cap off for use.*

FDA Label Image

Image (Insulin Glargine 47)

Instructional diagram showing how to twist and press the cap of an insulin injection pen to remove or attach the needle cover. The image includes arrows indicating the twisting motion and pressing pressure on the pen cap, suggesting user steps for needle handling on an insulin injection device.*

FDA Label Image

Image (Insulin Glargine 48)

An instructional illustration showing two hands removing a gray protective cap from a bottle and unscrewing a small white dropper cap from the bottle opening. The image likely depicts steps for opening a medication bottle, relevant to insulin glargine U-300 injection solution by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Insulin Glargine 49)

An instructional diagram showing a hand holding an insulin glargine U-300 injection pen and the other hand pulling off the pen cap. The injection pen is labeled with dosage markings and the brand name Insulin glargine U-300 is visible on the pen's label.*

FDA Label Image

Principal Display Panel (1.5 mL Pen Carton)

Insulin glargine U-300 SoloStar injection 300 units/mL subcutaneous solution in a prefilled pen. The label indicates single patient use, storage instructions, and manufacturer Winthrop, a Sanofi company. The carton includes three 1.5 mL prefilled pens, for a total of 450 units per pen.*

FDA Label Image

Principal Display Panel (3 mL Pen Carton)

Packaging label for Insulin glargine U-300 Max SoloStar injection, 300 units/mL strength. The label indicates it is for subcutaneous use only, dispensed as two 3 mL prefilled pens. The product is manufactured by Sanofi-Aventis U.S. LLC under the Winthrop brand. The label includes dosing adjustments by 2 units, storage instructions, and usage warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.